Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19

Page view(s)
334
Checked on Jul 04, 2024
Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19
Title:
Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19
Journal Title:
ACS Medicinal Chemistry Letters
Publication Date:
08 August 2022
Citation:
Chia, C. S. B., & See, Y. Y. (2022). Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19. ACS Medicinal Chemistry Letters, 13(9), 1388–1389. https://doi.org/10.1021/acsmedchemlett.2c00332
Abstract:
COVID-19 is a highly infectious disease caused by SARS-CoV-2. First reported in December 2019, it rapidly escalated into a global pandemic, resulting in over 6.3 million fatalities by July 4, 2022. The first oral coronavirus main protease inhibitor, nirmatrelvir, was granted Emergency Use Authorization by the U.S. FDA in December 2021. It is a tripeptide incorporated with a C-terminal nitrile designed to bind and form a covalent attachment to the SARS-CoV-2 main protease. Shortly after nirmatrelvir’s approval, Enanta Pharmaceuticals’ peptidomimetic SARS-CoV-2 main protease inhibitor entered clinical trials in February 2022. This patent highlight reports key structures of di- and tripeptide inhibitors described in Enanta Pharmaceuticals’ patent WO 2022/020242 A1.
License type:
Publisher Copyright
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001
Description:
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see doi.org/10.1021/acsmedchemlett.2c00332
ISSN:
1948-5875
Files uploaded: